Home » Newsletters » BioWorld Science

BioWorld Science

June 2, 2009

View Archived Issues

EMEA accepts for review Schering-Plough's MAA for Sycrest for schizophrenia and bipolar I disorder

Otsuka claims novel collagen production suppressant compounds for cancer treatment

Novel G-protein coupled receptor 40 agonists for the treatment of diabetes discovered by Merck & Co.

Janssen describes adenosine A2A receptor antagonists for the treatment of Parkinson's disease

Nissan Chemical presents P2X7 receptor antagonists for the treatment of rheumatoid arthritis

Dopamine D3 receptor ligands for the treatment of schizophrenia discovered by Abbott

KineMed and Bristol-Myers Squibb sign collaboration agreement in Alzheimer's disease

Meda completes seventh phase III study of azelastine nasal spray for allergic rhinitis

Phase II NT-501 trial demonstrates strong biological effect in retinitis pigmentosa

EMEA grants orphan drug designation for AMT-021 for acute intermittent porphyria

Cytori completes enrollment in PRECISE trial of Celution in chronic myocardial ischemia

Amarillo Biosciences provides update on phase II influenza study in Australia

BioPartners withdraws Biferonex (interferon beta-1a) application from EMEA

Catalyst reports results for phase II CPP-109 trial for cocaine addiction

CSL enters agreements with U.S. and Australian government for swine flu vaccine

FDA approves Besivance for bacterial conjunctivitis

Clinical Data acquires Avalon Pharmaceuticals

AstraZeneca provides regulatory update for Seroquel XR for MDD

Incyte changes primary endpoint for U.S. phase III COMFORT-I trial of INCB-18424

FDA issues complete response letter regarding Johnson & Johnson's NDA for rivaroxaban

Intercell initiates enrollment in phase II clinical trial of VE patch for H5N1 influenza

MediciNova amends dosing regimen for phase II MN-221-CL-007 trial of MN-221 in asthma

Target inhibition seen with Akt inhibitor MK-2206 in solid tumor patients

Phase I data on GDC-0941 in solid tumors reported

Oncolytic virus active in patients with neuroendocrine cancers

TAL-6004 safe and well tolerated in patients with alpha1-antitrypsin deficiency

Recently developed CRTH2 antagonist decreases allergic rhinitis responses in mice

Popular Stories

Today's news in brief
BioWorld
BioWorld briefs for March 16, 2026.
Precision psychiatry beyond, or before, biomarkers
BioWorld
There is broad agreement that psychiatric diagnoses in their current form are not reflective of any underlying biology, and that this is one of the things...
Keros reports beneficial effects of RKER-065 in ALS model
BioWorld Science
Keros Therapeutics Inc. has presented data regarding their activin receptor ligand trap, RKER-065, for the inhibition of the activin/myostatin signaling axis.
News in brief
BioWorld Asia
BioWorld Asia briefs for March 10, 2026
First-in-class POLG activator restores mtDNA across mutations
BioWorld Science
Researchers from Pretzel Therapeutics Inc. presented preclinical data of PX-578, a first-in-class POLG activator aimed at restoring mtDNA replication and...